MI-SLE, n (%) | Ntotal | MI-non-SLE, n (%) | Ntotal | P value | |
NSTEMI | 23 (72) | 32 | 21 (66) | 32 | 1.0* |
STEMI | 9 (28) | 32 | 11 (34) | 32 | |
MINOCA (0-VD) | 3 (12) | 26 | 10 (35) | 29 | 0.07* |
MI-CAD (≥1 VD) | 23 (88) | 26 | 19 (66) | 29 | |
0-VD | 3 (12) | 26 | 10 (35) | 29 | 0.04† |
1-VD | 13 (50) | 26 | 9 (31) | 29 | |
≥2-VD | 10 (39) | 26 | 10 (35) | 29 | |
LMCA involvement | 3 (12) | 26 | 0 (0) | 29 | 0.50* |
LAD involvement | 19 (73) | 26 | 17 (59) | 29 | 0.11* |
RCA involvement | 7 (27) | 26 | 9 (31) | 29 | 0.75* |
Cx involvement | 6 (23) | 26 | 6 (21) | 29 | 1.0* |
LVEF <50% | 13 (45) | 29 | 12 (36) | 33 | 0.79* |
LVEF ≥50% | 16 (55) | 29 | 21 (64) | 33 |
*The McNemar test was used.
†The Wilcoxon signed-rank test was used.
Cx, circumflex artery; LAD, left anterior descending artery; LMCA, left main coronary artery; LVEF, left ventricular ejection fraction; MI-CAD, MI with coronary artery disease; MINOCA, MI with non-obstructive coronary arteries; MI-non-SLE, MI patients without SLE; MI-SLE, MI patients with SLE; NSTEMI, non-ST-elevation MI; RCA, right coronary artery; STEMI, ST-elevation MI; 0-VD, 0-vessel disease; 1-VD, 1-vessel disease; 2-VD, 2-vessel disease.